The inherent complexity of cancer provides investigators and clinicians with a challenging mix of cells in various states to fully understand disease biology and inform therapeutic decisions. Empowering cancer researchers to explore fundamental biological questions that were previously inconceivable is why the Tapestri from Mission Bio was designed. Quantitative characterization of genotype and phenotype at the single-cell level reveals clonal phylogeny and selection at higher resolution, which should ultimately enable better personalized therapeutic selection. Thus, by identifying SNVs, CNVs and surface protein expression changes in the same cellular background, Tapestri enables comprehensive insights into disease progression, development of resistance, and measurable residual disease (MRD).
For this Inside Precision Medicine webinar, Dr. Todd Druley and Aaron Llanso discussed applying single-cell DNA sequencing to MRD, clonal hematopoiesis (CHIP), solid tumor, and precision medicine. They also cover how to track the clonal evolution of cancer with single-cell DNA sequencing and how to link genotype and phenotype with multiomics—all while providing new translational applications for the clinic.
